

## Current information disclosure

Curative Biotechnology, Inc. announced today that Kapil Bharti, Ph.D. of the National Eye Institute (NEI) at the National Institutes of Health (NIH) has joined the Curative Scientific and Clinical Advisory Board.

Dr. Bharti obtained his Ph.D. at the Johann Wolfgang Goethe University at Frankfurt in Germany. His Ph.D. work involved basic biology in the areas of heat stress, cellular chaperones, and epigenetics. From Germany, Dr. Bharti came to the National Institute of Neurological Disorders and Stroke to work with Dr. Heinz Arnheiter as a postdoctoral fellow. While there, he published numerous papers in the areas of transcription factor regulation, pigment cell biology, and the developmental biology of the eye.

This led him to develop an interest in the emerging field of stem cell biology, particularly of the retinal pigment epithelium. Dr. Bharti has authored numerous publications and has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Symposium.

In Dr. Bharti's work on NEI's Ocular Stem Cells and Translational Research (OSCTR) unit a major goal has been to perform translational research on degenerative eye diseases using induced pluripotent stem (iPS) cell technology. Dr. Bharti is the lead inventor on the patent claims in the United States and PCT (international) filings licensed by Curative Biotech from the NEI.

This technology which led to the development of in vitro disease models to study patient-specific disease processes is the basis for the patents filed worldwide which Curative Biotech has exclusively licensed.